Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhodobacter sphaeroides extract
- Development stage
- Preclinical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
Rhodobacter sphaeroides extract is a biologically active preparation derived from the probiotic photosynthetic bacterium Rhodobacter sphaeroides. It is rich in carotenoids (such as ζ-carotene, neurosporene, spheroidenone, and methoxyneurosporene), amino acids (notably glycine and arginine), and other bioactive compounds. The extract has demonstrated several biological activities:
- Enhances cell growth and viability more effectively than fetal bovine serum (FBS) in cell culture systems.
- Reduces oxidative stress by lowering intracellular reactive oxygen species.
- Stimulates lysosomal activity, supporting cellular homeostasis and autophagy.
- Exhibits anti-inflammatory effects by inhibiting cytokine production (e.g., TNF-α) through mechanisms such as blocking LPS receptor recognition.
- Shows protective effects against cisplatin-induced nephrotoxicity in animal models via anti-inflammatory and antioxidant actions.
- Inhibits melanogenesis through modulation of the MEK/ERK signaling pathway. The product Lycogen is a commercial form of this extract with enriched carotenoid content due to genetic modification of the source strain.
- Brand names
- Lycogen
- Other names
- Rhodobacter sphaeroides cell-free extractR. sphaeroides extractLycogen
02
Targets
Beyond the preview
Go deeper on Rhodobacter sphaeroides extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rhodobacter sphaeroides extract.